Why personality differences matter for social functioning and social structureWOLF, Max; KRAUSE, Jens.Trends in ecology & evolution (Amsterdam). 2014, Vol 29, Num 6, pp 306-308, issn 0169-5347, 3 p.Article

On the Evolution of Personalities via Frequency-Dependent SelectionWOLF, Max; MCNAMARA, John M.The American naturalist. 2012, Vol 179, Num 6, pp 679-692, issn 0003-0147, 14 p.Article

Animal personalities: consequences for ecology and evolutionWOLF, Max; WEISSING, Franz J.Trends in ecology & evolution (Amsterdam). 2012, Vol 27, Num 8, pp 452-461, issn 0169-5347, 10 p.Article

A prospective clinicopathologic study of dose-modified CODOX-M/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)MEAD, Graham M; BARRANS, Sharon L; WENDI QIAN et al.Blood. 2008, Vol 112, Num 6, pp 2248-2260, issn 0006-4971, 13 p.Article

Handheld gamma probe localization of accessory splenic tissue in recurrent idiopathic thrombocytopenic purpuraFINKELDE, David T; HICKS, Rodncy J; WOLF, Max et al.Archives of surgery (Chicago, IL. 1960). 2000, Vol 135, Num 9, pp 1112-1113, issn 0004-0010Article

Rapid assessment of the cost-effectiveness of low impact development for CSO controlMONTALTO, Franco; BEHR, Christopher; ALFREDO, Katherine et al.Landscape and urban planning. 2007, Vol 82, Num 3, pp 117-131, issn 0169-2046, 15 p.Article

Treatment-related myelodysplasia following fludarabine combination chemotherapyTAM, Constantine S; SEYMOUR, John F; PRINCE, H. Miles et al.Haematologica (Roma). 2006, Vol 91, Num 11, pp 1546-1550, issn 0390-6078, 5 p.Article

A prospective study of the separate predictive capabilities of ¹⁸[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-¹³¹-rituximab radio-immunotherapyBISHTON, Mark J; HICKS, Rodney J; WESTERMAN, David A et al.Haematologica (Roma). 2008, Vol 93, Num 5, pp 789-790, issn 0390-6078, 2 p.Article

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-hodgkin lymphomaTAM, Constantine S; WOLF, Max; PRINCE, H. Miles et al.Cancer. 2006, Vol 106, Num 11, pp 2412-2420, issn 0008-543X, 9 p.Article

The evolutionary and ecological consequences of animal social networks: emerging issuesKURVERS, Ralf H. J. M; KRAUSE, Jens; CROFT, Darren P et al.Trends in ecology & evolution (Amsterdam). 2014, Vol 29, Num 6, pp 326-335, issn 0169-5347, 10 p.Article

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphomaGANDHI, Maher K; LAMBLEY, Eleanore; MILLS, Tony et al.Clinical cancer research. 2006, Vol 12, Num 2, pp 460-464, issn 1078-0432, 5 p.Article

Prognostic impact of monocyte count at presentation in mantle cell lymphomaGEORGE, Anupkumar; PRINCE, Henry Miles; SZER, Jeff et al.British journal of haematology. 2014, Vol 164, Num 6, pp 890-893, issn 0007-1048, 4 p.Article

BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup StudyVAN OERS, Marinus H. J; TÖNNISSEN, Evelyn; HOLTE, Harald et al.Journal of clinical oncology. 2010, Vol 28, Num 13, pp 2246-2252, issn 0732-183X, 7 p.Article

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup StudyVAN OERS, Marinus H. J; VAN GLABBEKE, Martine; HAGENBEEK, Anton et al.Journal of clinical oncology. 2010, Vol 28, Num 17, pp 2853-2858, issn 0732-183X, 6 p.Article

Life-history trade-offs favour the evolution of animal personalitiesWOLF, Max; VAN DOORN, G. Sander; LEIMAR, Olof et al.Nature (London). 2007, Vol 447, Num 7144, pp 581-584, issn 0028-0836, 4 p.Article

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-hodgkin lymphoma in patients both with and without rituximab during induction : results of a prospective randomized phase 3 intergroup trial. CommentaryGHIELMINI, Michele; VAN OERS, Marinus H. J; HOLTE, Harald et al.Blood. 2006, Vol 108, Num 10, issn 0006-4971, 3235,3295-3301 [8 p.]Article

Fluorine-18 fluorodeoxyglucose Positron emission tomography, Gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphomaWIRTH, Andrew; SEYMOUR, John F; HICKS, Rodney J et al.The American journal of medicine. 2002, Vol 112, Num 4, pp 262-268, issn 0002-9343Article

A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignanciesTAM, Constantine S; WOLF, Max M; JANUSZEWICZ, E. Henry et al.Cancer. 2004, Vol 101, Num 9, pp 2042-2049, issn 0008-543X, 8 p.Article

Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignanciesTAM, Constantine S; WOLF, Max M; JANUSZEWICZ, E. Henry et al.Cancer. 2004, Vol 100, Num 10, pp 2181-2189, issn 0008-543X, 9 p.Article

The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disordersPOLIZZOTTO, Mark N; TAM, Constantine S; MILNER, Alvin et al.Cancer. 2006, Vol 107, Num 4, pp 773-780, issn 0008-543X, 8 p.Article

Mantle cell lymphoma with central nervous system involvement: frequency and clinical featuresGILL, Saar; HERBERT, Kirsten E; PRINCE, H. Miles et al.British journal of haematology. 2009, Vol 147, Num 1, pp 83-88, issn 0007-1048, 6 p.Article